摘要
肝细胞癌(hepatocellular carcinoma,HCC)是常见的恶性肿瘤之一。分子靶向药物索拉非尼是不能手术切除的进展期HCC的一线疗法。但部分HCC对其耐药性的出现影响了总体疗效,耐药可分为原发性(HCC原本就对索拉非尼缺乏敏感性)和获得性(开始敏感,治疗过程中出现耐药)两类,其机制尚不清楚。HCC对索拉菲尼的耐药机制主要表现在肝癌细胞自身和肿瘤微环境两个方面:前者包括细胞自噬、上皮-间质转化(epithelial-mesenchymal transition,EMT)、铁死亡(ferroptosis)受抑制和肿瘤起始细胞(tumor-initiating cell,TIC)等;后者包括外泌体(exosome)和血管选定等。本文对其相关研究进展进行总结。
Hepatocellular carcinoma(HCC)is one of themost prevalent human cancers all over the world.Sorafenib is the only first line proved treatment for advanced HCC patients.However,the emergence of sorafenib resistance impacts on the efficacy of HCC treatment,which canbe primary or acquired(primary sensitive?and resistant late during treatment process).At present?the mechanism of sorafenib resistance is not clear yet?which can be related to the aberrations in genetics and phenotype of HCC cells and the modifications in tumor microenvironment.The autophagy,epithelial-mesenchymal transition(EMT),ferroptosis,and tumor-initiating cells(T-ICs)phenotype of HCC cells,as well as exosomes and vessel co-option,have drawn much attentions in recent years.We summarized the progress of the related studies in this article.
作者
胡倍源
覃伟
董琼珠
钦伦秀
HU Bei-yuan;QIN Wei;DONG Qiong-zhu;QIN Lun-xiu(Department of General Surgery,Huashan Hospital,Fudan University,Shanghai 200040,China;Institute of Biomedical Sciences,Fudan University,Shanghai 200032,China;Cancer Metastasis Institute,Fudan University,Shanghai 200040,China)
出处
《复旦学报（医学版）》
CAS
CSCD
北大核心
2018年第6期884-888,共5页
Fudan University Journal of Medical Sciences
基金
国家自然科学基金(81372647
81672820
81772563)
十二五科技部重大专项计划(2012XZ10002012)~~
